FDA's Cialis Review Affected By Communication Problems: Lilly/Icos Asked To Be "More Forthcoming"
The companies felt that communication with the agency during the first review cycle was "not timely and productive." FDA Office of Drug Evaluation III Director and Lilly VP-Global Regulatory Affairs agree to "lessons learned" debriefing.